Bacterial Sinusitis Treatment Guidelines

Introduction to Bacterial Sinusitis

The American Academy of Otolaryngology-Head and Neck Surgery states that the most common pathogens in acute bacterial sinusitis are Streptococcus pneumoniae (33-41%), Haemophilus influenzae (29-35%), and Moraxella catarrhalis (4-8%) 1
The Infectious Diseases Society of America notes that in chronic sinusitis, the microbiology is typically polymicrobial with anaerobes (Bacteroides, Peptostreptococcus, Fusobacterium, and Veillonella) as predominant isolates 2, 3

The American Academy of Pediatrics recommends amoxicillin (500 mg twice daily for adults) as a standard first-line option for uncomplicated acute bacterial sinusitis 4, 3
The American Academy of Pediatrics suggests that for areas with high prevalence of β-lactamase-producing organisms or penicillin-resistant S. pneumoniae, amoxicillin-clavulanate (500-875 mg twice daily) is recommended 4, 5
The American Academy of Pediatrics recommends high-dose amoxicillin-clavulanate (80–90 mg/kg/day of amoxicillin component) for patients with moderate to severe illness or risk factors for resistant organisms 5

The American Academy of Allergy, Asthma, and Immunology states that second-generation cephalosporins like cefuroxime axetil and cefprozil have enhanced activity against β-lactamase–producing H. influenzae and M. catarrhalis 6
The American Academy of Allergy, Asthma, and Immunology notes that third-generation cephalosporins cefpodoxime and cefdinir are suitable agents for sinusitis 6

The Infectious Diseases Society of America recommends a standard treatment duration of typically 10-14 days for most antibiotics 3
The American Academy of Allergy, Asthma, and Immunology suggests that some newer agents like azithromycin may be given for 5 days after an initial loading dose 4
The American Academy of Allergy, Asthma, and Immunology advises that antibiotic treatment of uncomplicated viral upper respiratory tract infection is inappropriate and strongly discouraged 6, 7
The American Academy of Otolaryngology-Head and Neck Surgery notes that approximately 35% of patients with nasal/sinus symptoms will have negative bacterial cultures, with symptoms usually due to a primary viral process 1

The Taiwan pneumonia guidelines recommend using a second or third generation cephalosporin, such as cefuroxime, as the preferred alternative when 25-50% of non-typeable strains produce beta-lactamase, as amoxicillin and ampicillin should only be used when susceptibility is known 8
Second and third generation cephalosporins, including cefuroxime, are explicitly recommended for treatment of beta-lactamase producing H. influenzae, according to the Journal of Microbiology, Immunology and Infection 8

Among second-generation cephalosporins used for sinusitis and respiratory infections, cefuroxime axetil has enhanced activity against beta-lactamase-producing H. influenzae and M. catarrhalis, although it is less active against M. catarrhalis compared to some third-generation agents like cefpodoxime, as reported by the American Academy of Otolaryngology-Head and Neck Surgery 9, 10